Patent intelligence · WO
WO 2018175449
COMPOSÉS DE PROLINE AMIDE ET LEURS ANALOGUES D'AZÉTIDINE PORTANT UN RADICAL BENZYLE À SUBSTITUTION SPÉCIFIQUE
COMPOSÉS DE PROLINE AMIDE ET LEURS ANALOGUES D'AZÉTIDINE PORTANT UN RADICAL BENZYLE À SUBSTITUTION SPÉCIFIQUE
Patent details — WO 2018175449
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Sep 27, 2018
- Expiration
- Sep 22, 2038
- Applicant
- ABBVIE DEUTSCHLAND [DE]
- CPC classes
- A61K 31/ 40 A I, A61P 3/ 10 A I, A61P 9/ 00 A I, A61P 25/ 14 A I
Quick answer
WO 2018175449 (COMPOSÉS DE PROLINE AMIDE ET LEURS ANALOGUES D'AZÉTIDINE PORTANT UN RADICAL BENZYLE À SUBSTITUTION SPÉCIFIQUE) is held by ABBVIE DEUTSCHLAND [DE]. Status: granted. Granted Sep 27, 2018. Expires Sep 22, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABBVIE DEUTSCHLAND [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 40 A I, A61P 3/ 10 A I, A61P 9/ 00 A I, A61P 25/ 14 A I, A61P 25/ 18 A I, A61P 25/ 22 A I
More from ABBVIE DEUTSCHLAND [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2024243450
MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET
granted -
CA 3266054
COMPOSÉS DE N-MÉTHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE
granted -
CA 3259391
POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1
granted -
CA 3245150
COMBINAISONS AVEC UN ANTICORPS ANTI-CD39 HUMAIN, UN ANTICORPS ANTI-PD-1 HUMAIN ET UNE CHIMIOTHÉRAPIE CONTRE LE CANCER GASTRIQUE
granted -
US 2023174645
ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS
granted -
CA 3235096
METHODES DE TRAITEMENT DE L'ANEMIE CAUSEE PAR UNE MALADIE RENALE
granted -
CA 3207179
METHODES DE TRAITEMENT DE LA MALADIE DE CROHN ET DE LA COLITE ULCEREUSE
granted -
US 2022169620
SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS
granted
Frequently asked questions
What is US patent 2018175449?
WO 2018175449 (COMPOSÉS DE PROLINE AMIDE ET LEURS ANALOGUES D'AZÉTIDINE PORTANT UN RADICAL BENZYLE À SUBSTITUTION SPÉCIFIQUE) is held by ABBVIE DEUTSCHLAND [DE]. Status: granted. Granted Sep 27, 2018. Expires Sep 22, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2018175449?
ABBVIE DEUTSCHLAND [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.
When does WO 2018175449 expire?
Our index shows an expiration date of Sep 22, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.